Allarity Therapeutics, Inc. (ALLR)

1.3700 +0.1000 (+7.87%) At close: 04:00PM EDT

Allarity Therapeutics, Inc.

24 School Street
2nd Floor
Boston, MA 02108
United States
401 426 4664
https://www.allarity.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Thomas H. Jensen	Founder, CEO, Senior VP of Investor Relations & Director	N/A	N/A	1978
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.	Co-Founder	546.08k	N/A	1955
Dr. Steen Meier Knudsen Ph.D.	Founder & Chief Scientific Officer	185.11k	N/A	1961

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Corporate Governance

Allarity Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.